Korro Bio, Inc., a Cambridge, Mass.-based RNA editing company focused on the discovery and development of novel genetic medicines, closed a $116M Series B financing. The round was led by Ev... 原文链接
本文新闻来源www.finsmes.com,版权归原作者所有,内容仅代表作者本人观点,不代表企查查的立场。如有任何疑问或需要删除,请联系
kefu@qichacha.com